SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature [see comments]. Chest 1994; 106(3): 8615.
  • 2
    Cellerino R, Tummarello D, Guidi F, Isidori P, Raspubli M, Biscottini B, et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 1991; 9(8): 145361.
  • 3
    Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer—report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6(4): 63341.
  • 4
    Sandler AB, Nemunaitis J, Denham C, von Powel J, Cormier Y, Gatzemeier U, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18(1): 12230.
  • 5
    Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, et al. Randomized trial comparing cisplatin with cisplatin plus navelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16: 245965.
  • 6
    Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18(3): 62331.
  • 7
    Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9(9): 161826.
  • 8
    Jiroutek M, Johnson D, Blum R, Bonomi P, Ruckdeschel J, Schiller J, Sandler A. Prognostic factors in advanced non-small cell lung cancer (NSCLC): analysis of Eastern Cooperative Oncology Group trials from 1981–1992 [abstract]. Proc Am Soc Clin Oncol 1998; 17: 461.
  • 9
    Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995;13(5): 122130.
  • 10
    Ramanathan RK, Belani, CP. Chemotherapy for advanced non-small cell lung cancer: past present and future. Semin Oncol 1997; 24: 44054.
  • 11
    Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 1999; 85(9): 202332.
  • 12
    Schiller J, Harrington D, Sandler A, Belani C, Langer C, Krrok J, et al. A randomized Phase III trial of four chemotherapy regimens in advanced non-small lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2000; 19: 1.
  • 13
    Stewart LA, Pignon JP. Non Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer. Meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311: 899907.
  • 14
    Manegold C, Bergman B, Chemaissani A, Dornoff W, Drings P, Kellokumpu-Lehtinen P, et al. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised Phase II study in locally advanced or metastatic non-small cell lung cancer. Ann Oncol 1997; 8: 5259.
  • 15
    Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients [see comments]. J Clin Oncol 1994; 12(2): 3607.
  • 16
    Belani CP, Natale JS, Lee M, Socinski M, Waterhouse D, Rowland K, et al. Randomized Phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer [abstract]. Proc Am Assoc Clin Oncol 1998; 17: 455.
  • 17
    Masuda N, Fukuoka M, Negoro S, Takada Y, Sugiura T, Ohashi Y, et al. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter Phase III trial [abstract]. Proc Am Soc Clin Oncol 1999; 18: 459.
  • 18
    Niho S, Nagao K, Nishiwaki A, Yokoyama A, Saijo N, Ohashi Y, Niitani H. Randomized Phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1999; 18: 492.
  • 19
    Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, et al. Gemcitabine plus best supportive care (BSC) vs BSC inoperable non-small cell lung cancer—a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-small cell lung cancer. Br J Cancer 2000;83: 44753.
  • 20
    Feliu J, Gomez LL, Madronal C, Espinosa E, Espinoza J, Garcia Giron C, et al. Gemcitabine plus vinorelbine in non-small cell lung carcinoma patients age 70 years or older or patients who can not receive cisplatin. Cancer 1999; 86: 14639.
  • 21
    Gridelli C, Perrone F, Gallo C. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 6672.
  • 22
    Herbst RS, Khuri FR, Jung FV, Fossella FV, Lee JS, Glisson B, et al. Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1999; 18: 462.
  • 23
    Lilenbaum R, Cano R, Schwartz M, Siegel L, Lutzky J, Lewis M, et al. Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: a Phase II study. Cancer 2000; 88(3): 55762.
  • 24
    Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18(13): 252936.
  • 25
    Gridelli C, Perrone F, Cigolari S, Manzione L, Piantedosi F, Barbara S, et al. The MILES (Multicenter Italian Lung Cancer Study in the Elderly Study) Phase 3 trial: gemcitabine + vinorelbine versus vinorelbine versus gemcitabine in elderly advanced NSCLC patients [abstract]. Proc Am Soc Clin Oncol 2001; 20: 308.
  • 26
    Kosmidis P, Mylonakis N, Skarlos D, Samantas E, Dimopoulos M, Papadimitriou C, et al. Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2000;11(7): 799805.
  • 27
    Bunn PA Jr., Kelly K. A Phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol 1995;22(4 Suppl 9 ): 26.
  • 28
    Muggia FM, Vafai D, Natale R, Israel V, Zaretsky S, McRae A, et al. Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose escalation trials. Semin Oncol 1995; 22: 636.
  • 29
    Rowinsky EK, Flood WA, Sartorius SE, Bowling MK, Wagner J, Ettinger DS. Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. Semin Oncol 1995; 22(4 Suppl 9 ): 4854.
  • 30
    Giaccone G, Huizing M, Postmus PE, ten Bokkel Huinink WW, Koolen M, van Zandwijk N, et al. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer. Semin Oncol 1995; 22(4 Suppl 9 ): 7882.
  • 31
    Rosell R, Tonato M, Sandler A. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer. Semin Oncol 1998; 25(4 Suppl 9 ): 2734.
  • 32
    Rinaldi M, Crino L, Scagliotti GV, Mosconi AM, De Marinis F, Gridelli C, et al. A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a Phase II randomized trial. Ann Oncol 2000; 11(10): 1295300.